Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
4445 | 1711 | 39.2 | 92% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | SURVIVIN | Author keyword | 698 | 51% | 57% | 972 |
2 | YM155 | Author keyword | 155 | 96% | 3% | 48 |
3 | SURVIVIN EXPRESSION | Author keyword | 21 | 85% | 1% | 11 |
4 | BIRC5 | Author keyword | 12 | 49% | 1% | 18 |
5 | SEPANTRONIUM BROMIDE | Author keyword | 12 | 86% | 0% | 6 |
6 | SURVIVIN 2B | Author keyword | 12 | 86% | 0% | 6 |
7 | OTORHINOLARYNGOL MOL CELLULAR ONCOL | Address | 8 | 75% | 0% | 6 |
8 | SURVIVIN DELTA EX3 | Author keyword | 8 | 100% | 0% | 5 |
9 | SURVIVIN SPLICE VARIANTS | Author keyword | 8 | 100% | 0% | 5 |
10 | SURVIVING | Author keyword | 8 | 39% | 1% | 15 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | SURVIVIN | 698 | 51% | 57% | 972 | Search SURVIVIN | Search SURVIVIN |
2 | YM155 | 155 | 96% | 3% | 48 | Search YM155 | Search YM155 |
3 | SURVIVIN EXPRESSION | 21 | 85% | 1% | 11 | Search SURVIVIN+EXPRESSION | Search SURVIVIN+EXPRESSION |
4 | BIRC5 | 12 | 49% | 1% | 18 | Search BIRC5 | Search BIRC5 |
5 | SEPANTRONIUM BROMIDE | 12 | 86% | 0% | 6 | Search SEPANTRONIUM+BROMIDE | Search SEPANTRONIUM+BROMIDE |
6 | SURVIVIN 2B | 12 | 86% | 0% | 6 | Search SURVIVIN+2B | Search SURVIVIN+2B |
7 | SURVIVIN DELTA EX3 | 8 | 100% | 0% | 5 | Search SURVIVIN+DELTA+EX3 | Search SURVIVIN+DELTA+EX3 |
8 | SURVIVIN SPLICE VARIANTS | 8 | 100% | 0% | 5 | Search SURVIVIN+SPLICE+VARIANTS | Search SURVIVIN+SPLICE+VARIANTS |
9 | SURVIVING | 8 | 39% | 1% | 15 | Search SURVIVING | Search SURVIVING |
10 | SURVIVIN PROTEIN HUMAN | 6 | 80% | 0% | 4 | Search SURVIVIN+PROTEIN++HUMAN | Search SURVIVIN+PROTEIN++HUMAN |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | ANTI APOPTOSIS GENE | 481 | 77% | 19% | 331 |
2 | PROTEIN SURVIVIN | 262 | 86% | 8% | 132 |
3 | ANTIAPOPTOSIS GENE | 109 | 84% | 3% | 59 |
4 | TARGETING SURVIVIN | 79 | 79% | 3% | 50 |
5 | NUCLEAR SURVIVIN | 68 | 82% | 2% | 40 |
6 | SURVIVIN DELTA EX3 | 55 | 87% | 2% | 27 |
7 | APOPTOSIS INHIBITOR | 40 | 76% | 2% | 28 |
8 | YM155 | 29 | 75% | 1% | 21 |
9 | SMALL MOLECULE SUPPRESSOR | 29 | 88% | 1% | 14 |
10 | NORMAL CORD BLOOD | 29 | 67% | 2% | 26 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Opinion - Survivin, cancer networks and pathway-directed drug discovery | 2008 | 504 | 96 | 61% |
Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers | 2015 | 2 | 54 | 70% |
MicroRNA regulation and therapeutic targeting of survivin in cancer | 2015 | 3 | 80 | 45% |
Survivin - The inconvenient IAP | 2015 | 2 | 108 | 63% |
Survivin: A new target for anti-cancer therapy | 2009 | 187 | 142 | 69% |
Survivin beyond physiology: Orchestration of multistep carcinogenesis and therapeutic potentials | 2014 | 14 | 94 | 80% |
Survivin as a Preferential Target for Cancer Therapy | 2014 | 16 | 138 | 70% |
Treat cancers by targeting survivin: Just a dream or future reality? | 2013 | 29 | 96 | 75% |
Survivin, a cancer target with an emerging role in normal adult tissues | 2006 | 202 | 137 | 88% |
Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin | 2011 | 62 | 119 | 83% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | OTORHINOLARYNGOL MOL CELLULAR ONCOL | 8 | 75% | 0.4% | 6 |
2 | DIAGNOVA | 4 | 75% | 0.2% | 3 |
3 | BOYER MOL MED 436B | 3 | 100% | 0.2% | 3 |
4 | IMMUNOL INFLAMMAT MED | 3 | 100% | 0.2% | 3 |
5 | VA CARDIAC | 3 | 60% | 0.2% | 3 |
6 | EF WL MCKNIGHT BRAIN | 2 | 67% | 0.1% | 2 |
7 | RADIAT ONCOLVANDERBILT CLIN B902 | 2 | 67% | 0.1% | 2 |
8 | PROSTATE CANC DISCOVERY DEV PROGRAM | 2 | 21% | 0.5% | 9 |
9 | SECT GEN PATHOL EXPT ONCOL | 2 | 40% | 0.2% | 4 |
10 | BIOTECHNOL INTERDISCIPLINARY BIOSCI BIODEAK | 2 | 27% | 0.4% | 6 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000217267 | LIVIN//XIAP//SMAC MIMETICS |
2 | 0.0000061417 | AURORA A//AURORA KINASES//AURORA KINASE |
3 | 0.0000051498 | BIKDD//MITOCHONDRIAL CYTOCHROME C RELEASE//BAX OVEREXPRESSION |
4 | 0.0000050852 | LARREA DIVARICATA CAV//NDGA//NORDIHYDROGUAIARETIC ACID |
5 | 0.0000044314 | CASP10//CASP8//CASPASE 10 |
6 | 0.0000033218 | REVERSINE//MITOTIC CATASTROPHE//WP 631 |
7 | 0.0000032366 | BCL 2//BCL 2 PROTEIN//BCL X |
8 | 0.0000029241 | NMP22//UROVYSION//URINE CYTOLOGY |
9 | 0.0000028436 | GRIM 19//OLFACTOMEDIN 4//GW112 |
10 | 0.0000027559 | AS101//SAFDIE AIDS IMMUNOL//CAIR |